Ansamycin antibiotics inhibit Akt activation and cyclin D expression in C. Partovian, M. Simons, Regulation of protein kinase B/ Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells, Cell Signal.6 (2004) 951?57. X. Fang, S. Yu, J.L. Tanyi, Y. Lu, J.R. Woodgett, G.B. Mills, Convergence of multiple signaling cascades at Temozolomide glyco- gen synthase kinase 3: Edg receptor-mediated phosphoryla- tion and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway, Mol. Cell. Biol. 22 (2002) 2099?110. N. Goode, K. Hughes, J.R. Woodgett, P.J. Parker, Dieren- tial regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes, J. Biol. Chem. 267 (1992)6878?6882. D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, Nature 378 (1995) 785?789. J.R. Gra, A.M. McNulty, K.R. Hanna, B.W. Konicek, R.L. Lynch, S.N. Bailey, C. Banks, A. Capen, R. Goode, J.E. Lewis, L. Sams, K.L. Huss, R.M. Campbell, P.W. Iversen, B.L. Neubauer, T.J. Brown, L. Musib, S. Geega- nage, D. Thornton, The protein kinase Cbeta-selective inhibitor
Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and sup- presses growth of human colon cancer and glioblastoma xenografts, Cancer Res. 65 (2005) 7462?469. M.A. Carducci, L. Musib, M.S. Kies, R. Pili, M. Truong, J.R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, N. Enas, V. Sinha, D.E. Thornton, R.S. Herbst, Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer, J. Clin. Oncol. 24 (2006) 4092?099. R.S. Herbst, Targeted therapy using novel agents in the treatment of non-small-cell lung cancer, Clin. Lung Cancer 3 (Suppl) (2002) Temozolomide 85622-93-1 . D.R. Premkumar, B. Arnold, I.F. Pollack, Cooperative inhibitory eect of ZD1839 (Iressa) in combination with7- AAG on glioma cell growth, Mol. Carcinog. 45 (2006) 288?301. P.A. Clarke, I. Hostein, U. Banerji, F.D. Stefano, A. Maloney, M. Walton, I. Judson, P. Workman, Gene expression proing of human colon cancer cells following inhibition of signal transduction by7-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecu- lar chaperone, Oncogene9 (2000) 4125?133. I. Hostein,
D. Robertson, F. DiStefano, P. Workman, P.A. Clarke, Inhibition of signal transduction by the Hsp90 inhibitor7-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis, Cancer Res. 61 (2001) 4003?4009. P.N. Munster, D.C. Marchion, A.D. Basso, N. Rosen, Degradation of HER2 by ansamycins induces growth arrest and buy Temozolomide apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3 0 -kinase-AKT-dependent path- way, Cancer Res. 62 (2002) 3132?137. N. Fujita, S. Sato, A. Ishida, T. Tsuruo, Involvement of Hsp90 in signaling and stability of 3-phosphoinositide- dependent kinase-1, J. Biol. Chem. 277 (2002)0346?0353. S. Sato, N. Fujita, T. Tsuruo, Modulation of Akt kinase activity by binding to Hsp90, Proc. Natl. Acad. Sci. USA 97 (2000)0832?0837. breast cancer cells that overexpress HER2, Oncogene 21 (2002)159?166. [25] W. Xu, E. Mimnaugh, M.F. Rosser, C. Nicchitta, M. Marcu, Y. Yarden, L. Neckers, Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90, J. Biol.
Chem. 276 (2001) 3702?708. [26] T.L. Riss, R.A. Moravec, Use of multiple assay applied science endpoints to investigate the eects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays, Assay Drug Dev. Technol. 2 (2004) 51?2. [27] E.P. Jane, D.R. Premkumar, I.F. Pollack, AG490 inences UCN-01-induced cytotoxicity in glioma cells in a p53- dependent fashion, correlating with eects on BAX cleavage and BAD phosphorylation, Cancer Lett. 257 (2007) 36?6. [28] X. Liu, C.N. Kim, J. Yang, R.